Latest Oncology News

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Conor Killmurray

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

September 19th 2021

Matthew Fowler

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021

Jamie Cesanek

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Colleen Moretti

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

September 19th 2021

Ryan McDonald

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

Latest Oncology Videos

All Oncology News

Oral GnRH Antagonist Therapy for mCSPC

September 13th 2021

Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.

Case 4: Treatment and Management Considerations in MCL

September 13th 2021

Sa Wang, MD, MD Anderson Cancer Center

The panel of experts in SM discuss the diagnosis and treatment of a 68-year-old female with mast cell leukemia.

Review of GEMSTONE-301 and -302 Data

September 13th 2021

Mark A. Socinski, MD,

Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.

Case 4: A 68-Year-Old Female With Mast Cell Leukemia

September 13th 2021

Sa Wang, MD, MD Anderson Cancer Center

Sa Wang, MD, presents the case of a 68-year-old female with mast cell leukemia.

Impact of Cytopenias on MF Treatment

September 13th 2021

Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center

Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the importance of allele burden in myelofibrosis (MF) and how cytopenias can limit treatment options for patients with myelofibrosis.

mCSPC: Applying New Data into Clinical Practice

September 13th 2021

Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.

Olaparib/Pembrolizumab Combo Continues to Show Promising Activity in mCRPC

September 12th 2021

Janelle Hart

The combination of olaparib and pembrolizumab continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who previously received docetaxel.

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

September 12th 2021

Steven Kaplan, MD

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Darolutamide Delays Time to Deterioration in HRQoL Related to Urinary and Bowel Symptoms in nmCRPC

September 12th 2021

Benjamin Saylor

Darolutamide was linked with a reduction in locally invasive procedures, delayed time to deterioration in health-related quality of life related to urinary and bowel symptoms in patients with nonmetastatic castration-resistant prostate cancer.

Enzalutamide/ADT Maintains Efficacy Regardless of Prior Antiandrogen Therapy in mHSPC

September 12th 2021

Courtney Marabella

Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.

Dr. Williams on the Rationale for the SunRISE-2 Trial in Muscle-Invasive Bladder Cancer

September 12th 2021

Stephen Williams, MD

Stephen B. Williams, MD, discusses the rationale for the phase 3 SunRISE-2 trial in muscle-invasive bladder cancer.

Dr. Schjesvold on OCEAN Trial Takeaways With Melflufen in Relapsed/Refractory Myeloma

September 12th 2021

Fredrik Schjesvold, MD, PhD

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.

Melflufen/Dexamethasone Improves PFS in Transplant-Naïve Relapsed/Refractory Multiple Myeloma

September 12th 2021

Matthew Fowler

Melphalan flufenamide (melflufen) plus dexamethasone demonstrated an improvement in progression-free survival vs pomalidomide/dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma.

Dr. Garon on the Efficacy of Datopotamab Deruxtecan in NSCLC

September 11th 2021

Edward Garon, MD

Edward B. Garon, MD, discusses the efficacy of datopotamab deruxtecan in patients with non–small cell lung cancer, as reported in the phase 1 TROPION-PanTumor01 trial.

Dr. Osarogiagbon on Geographic Disparities in Lung Cancer Mortality Rates in the United States

September 11th 2021

Raymond U. Osarogiagbon, MD, FACP

Raymond U. Osarogiagbon, MD, discusses geographic disparities in lung cancer mortality rates across the United States.

See All News